Clinical Trial Update: The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)

View source ↗

Summary

This clinical trial update discusses the potential predictive role of PD-L1 expression and neutrophil-to-lymphocyte ratio in selecting patients with non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: To Define an Easy and Feasible Panel Which May be Routinely Applied to Select Patients for Immunotherapy Avoiding More Complex and Expensive Methods | Status: UNKNOWN